Henry, Bringing a drug from discovery to the pharmacy shelf in 7 years IS quite an accomplishment, and LGND employees and shareholders ARE proud of such a feat.
I'm sure Ron Evans feels particularly pleased at this moment. I'm sure this a big day for you too, Henry, and I can understand your excitement. You've even told the Cisco thread about the news! ;-) Why not!! <VBG>
I'm happy that this one came in ahead of Seragen's drug.
I never anticipated any long-term price pop because of this news (and this doesn't bother me -- a vastly more significant event will hopefully happen this year). The street isn't deaf, dumb, and blind -- and so the Panretin Gel news has long been built into the price, imo. And the Street knows the difference between a gel and a systemic drug.
I do *guess* that this success will dampen some of the stock's price volatility.
The "nonsense on the thread" never intimated problems with this drug. Rather, contrarians objected to what seemed to be overly optimistic predictions of the stock's early price appreciation due to the drug, and over confidence that flurries of analyst reports and stock-promoter blurbs (eg Murphy, Individual Investor) would drive up (and sustain) the price. The "nonsense" folks are merely trying to caution regulars and newbies (and themselves <ng> ) -- during times giddy with "the sweet smell of hype" (great image, Bob!) -- that it's better to buy low and sell high, than the reverse.
In my view, one of the biggest plusses from this milestone: Ligand now has under its belt experience in navigating complicated dealings with the FDA -- experience invaluable for efficiently promoting its future, more important filings.
Happy day, Henry!
Regards, Cheryl |
